1. Good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, June 2020 Subject(s): Biological ProductsCOVID-19 -- prevention & controlDrug IndustryManufacturing and Industrial FacilitiesUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
2. Resuming normal drug and biologics manufacturing operations during the COVID-19 public health emergency Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, September 2020 Subject(s): Biological ProductsDrug IndustryManufacturing and Industrial FacilitiesCOVID-19United StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
